These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 8218853)
1. Rebound increase of PAI-1 following local intra-arterial rt-PA infusion, a possible cause of reocclusion. Astedt B; Casslén B; Lecander I; Nilsson L; Norgren L Blood Coagul Fibrinolysis; 1993 Aug; 4(4):563-7. PubMed ID: 8218853 [TBL] [Abstract][Full Text] [Related]
2. D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease. Koppensteiner R; Speiser W; Minar E; Ahmadi R; Ehringer H Thromb Haemost; 1990 Oct; 64(2):192-5. PubMed ID: 2125370 [TBL] [Abstract][Full Text] [Related]
3. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779 [TBL] [Abstract][Full Text] [Related]
4. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203 [TBL] [Abstract][Full Text] [Related]
5. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814 [TBL] [Abstract][Full Text] [Related]
6. A new intra arterial rt-PA dosage regimen in peripheral arterial occlusion: bolus followed by continuous infusion. Juhan C; Haupert S; Miltgen G; Girard N; Dulac P Thromb Haemost; 1991 May; 65(5):635. PubMed ID: 1908142 [No Abstract] [Full Text] [Related]
7. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462 [TBL] [Abstract][Full Text] [Related]
8. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013 [TBL] [Abstract][Full Text] [Related]
9. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis. Chen LY; Nichols WW; Saldeen TG; Mehta JL J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429 [TBL] [Abstract][Full Text] [Related]
10. [Local low dosage thrombolysis with rt-PA. Systemic effects on the fibrinolytic system--data on the assessment of the value and risk of this method]. von Bilderling P; Spannagl M; Mietaschk A; Iven M; Schramm W; Hess H Vasa Suppl; 1991; 33():132-3. PubMed ID: 1788645 [TBL] [Abstract][Full Text] [Related]
11. [Local intra-arterial thrombolysis with low dosage rt-PA. Thrombolysis in arterial occlusive disease of the leg]. Weidauer T; Timmermann J Fortschr Med; 1990 Dec; 108(36):700-2. PubMed ID: 2128294 [TBL] [Abstract][Full Text] [Related]
12. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. Collen D; Van de Werf F Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077 [TBL] [Abstract][Full Text] [Related]
13. [Local thrombolysis in peripheral arterial occlusion]. Hess H Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076 [TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219 [TBL] [Abstract][Full Text] [Related]
16. Alterations in the fibrinolytic system components during acute myocardial infarction. Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123 [TBL] [Abstract][Full Text] [Related]
17. Local intra-arterial fibrinolysis in acute hemispheric stroke: effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome. Eckert B; Kucinski T; Neumaier-Probst E; Fiehler J; Röther J; Zeumer H Cerebrovasc Dis; 2003; 15(4):258-63. PubMed ID: 12686789 [TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822 [TBL] [Abstract][Full Text] [Related]